- Home
- KFY vs PTGX Comparison
KFY vs PTGX Comparison
Compare KFY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KFY | PTGX |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 5.4B |
| IPO Year | 1999 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KFY | PTGX |
|---|---|---|
| Price | $66.27 | $89.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $78.00 | ★ $86.44 |
| AVG Volume (30 Days) | 356.2K | ★ 898.7K |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 33.45 | N/A |
| EPS | ★ 4.69 | 0.72 |
| Revenue | ★ $2,763,755,000.00 | $209,217,000.00 |
| Revenue This Year | $4.54 | N/A |
| Revenue Next Year | $4.41 | $296.47 |
| P/E Ratio | ★ $14.10 | $124.48 |
| Revenue Growth | ★ 0.93 | N/A |
| 52 Week Low | $59.23 | $33.70 |
| 52 Week High | $78.50 | $93.25 |
Technical Indicators
Market Signals| Indicator | KFY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 64.67 |
| Support Level | $65.17 | $83.52 |
| Resistance Level | $67.25 | $90.85 |
| Average True Range (ATR) | 1.34 | 2.63 |
| MACD | 0.40 | -0.33 |
| Stochastic Oscillator | 75.51 | 83.62 |
Price Performance
Historical ComparisonAbout KFY Korn Ferry
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.